Lima TB Treatment Default Data

The attached information is the minimum necessary to reproduce our results

Risk factors associated with early mycological clearance in cases with HIV-associated CM in Peru^*.

<p>Risk factors associated with early mycological clearance in cases with HIV-associated CM in Peru^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0174459#t003fn001" target="_blank">*</a>}.</p

Comparison of baseline characteristics according to the status of early mycological clearance (success vs failure) among cases with HIV-associated CM in Peru^*.

<p>Comparison of baseline characteristics according to the status of early mycological clearance (success vs failure) among cases with HIV-associated CM in Peru^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0174459#t002fn001" target="_blank">*</a>}.</p

Flow of cohort study participants.

<p>We initially enrolled 1294 pulmonary, smear-positive tuberculosis patients into the study. One patient was excluded since the doctor stopped treatment early. Fifteen patients were excluded since there was no record of their treatment outcome on file. We excluded 45 patients from the analysis who were missing at least one predictor variable. Of the initial 1294 patients enrolled, 1233 remained for analysis.</p

Factors associated with early mycological clearance in HIV-associated cryptococcal meningitis

<div><p>Introduction</p><p>The first-line combination therapy for HIV-associated cryptococcal meningitis (CM), a condition of high mortality particularly in the first two weeks of treatment, consists of amphotericin B plus flucytosine (5-FC). Given that 5-FC remains unavailable in many countries, the knowledge of factors influencing mycological clearance in patients treated with second-line therapy could contribute to effective management.</p><p>Objectives</p><p>To determine the factors associated with the clearance of <i>Cryptococcus</i> sp. from the cerebrospinal fluid by the second week of effective antifungal therapy (early mycological clearance) in HIV-associated CM.</p><p>Methods</p><p>Retrospective cohort study based on secondary data corresponding to HIV-associated CM cases hospitalized at a tertiary health care center in Lima, Peru where 5-FC remains unavailable. Risk factors associated with early mycological clearance were analyzed by generalized linear regression models.</p><p>Results</p><p>From January 2000 to December 2013, 234 individuals were discharged with a diagnosis of HIV-associated CM; in 215 we retrieved the required data. The inpatient mortality was 20% (43/215), 15 of them in the first two weeks of treatment. In the final model (157 cases), adjusted for age, previous episode of CM, ART use, type of antifungal treatment, raised intracranial pressure, frequency of therapeutic lumbar punctures, baseline fungal burden and treatment period, the factors associated with early mycological clearance were: Amphotericin B deoxycholate plus fluconazole as combination therapy (RR, 1.56; 95% CI, 1.14–2.14); severe baseline intracranial pressure (≥35 cm H₂O) (RR, 0.57; 95% CI, 0.33–0.99); and baseline fungal burden over 4.5 log₁₀ CFU/mL (RR, 0.61 95% CI: 0.39–0.95).</p><p>Conclusions</p><p>In a setting without access to first-line therapy for CM, the combination therapy with amphotericin B deoxycholate plus fluconazole was positively associated with early mycological clearance, while high fungal burden and severe baseline intracranial pressure were negatively associated, and thus related to failure.</p></div

Characteristics of 1,233 smear-positive pulmonary tuberculosis patients.

<p>Characteristics of 1,233 smear-positive pulmonary tuberculosis patients.</p

Comparison of baseline clinical and laboratory characteristics between included and excluded cases with HIV-associated CM in Peru^*.

<p>Comparison of baseline clinical and laboratory characteristics between included and excluded cases with HIV-associated CM in Peru^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0174459#t001fn001" target="_blank">*</a>}.</p

Additional file 1: of Diagnostic accuracy of nucleic acid amplification tests (NAATs) in urine for genitourinary tuberculosis: a systematic review and meta-analysis

Complete search strategy and details on quality evaluation. (DOCX 18 kb

Univariate model of MDE as hazard factor for Negative Outcome.

<p>MDE: Major Depressive Episode; HR: Hazard Ratio; CI 95%: 95% Confidence interval.</p

Negative Outcomes Survival Kaplan-Meier curve by MDE at baseline.

<p>Negative Outcomes Survival Kaplan-Meier curve by MDE at baseline.</p